What does that have to do with taxpayer funded R&D for medicine?
Presumably, taneq's point was that medicine owned by taxpayers can be sold at the cost to manufacture and distribute it at far lower costs, as opposed to the current system where the owners of the research also needed to be compensated.
Most (if not all) new medicines came out of basic research supported by the NIH. This research was tweaked and patented by companies who profit from selling the drugs. Is start-to-finish government drug pipeline a better solution? Perhaps, but current academic culture doesn't support it. It's not just about pouring more taxpayer money.
Presumably, taneq's point was that medicine owned by taxpayers can be sold at the cost to manufacture and distribute it at far lower costs, as opposed to the current system where the owners of the research also needed to be compensated.